You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension

Article metrics

Article menu

Download PDFPDF

Pulmonary vascular disease
Protocol
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension

 

Online download statistics by month:

Online download statistics by month: February 2018 to March 2024

AbstractFullPdf
Feb 201820720318
Mar 201811511843
Apr 2018595918
May 2018494911
Jun 201851527
Jul 201836364
Aug 201847466
Sep 201845455
Oct 201839399
Nov 201858589
Dec 201839394
Jan 201942408
Feb 201928285
Mar 2019454614
Apr 2019423417
May 201946449
Jun 201933287
Jul 2019333314
Aug 2019515011
Sep 201930304
Oct 201944419
Nov 2019352814
Dec 201916162
Jan 202027275
Feb 202031318
Mar 2020222014
Apr 202019197
May 202017165
Jun 202019184
Jul 2020151512
Aug 2020776
Sep 2020282813
Oct 2020232315
Nov 2020292411
Dec 202023233
Jan 202147437
Feb 202135343
Mar 202120185
Apr 2021252513
May 202118179
Jun 202122192
Jul 202120208
Aug 202119186
Sep 202122209
Oct 2021191914
Nov 2021181821
Dec 202138383
Jan 202239418
Feb 202215161
Mar 2022353514
Apr 2022343413
May 202226269
Jun 202228268
Jul 202223215
Aug 202217175
Sep 2022333114
Oct 202254538
Nov 2022141311
Dec 2022232413
Jan 202320159
Feb 202343437
Mar 202322228
Apr 2023161619
May 202312126
Jun 202315146
Jul 2023191410
Aug 20231796
Sep 2023181812
Oct 202326269
Nov 202311115
Dec 202338356
Jan 202410101
Feb 202411118
Mar 2024101039
Total23822305711